Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis.
Le Naour J, Montégut L, Pan Y, Scuderi SA, Cordier P, Joseph A, Sauvat A, Iebba V, Paillet J, Ferrere G, Brechard L, Mulot C, Dubourg G, Zitvogel L, Pol JG, Vacchelli E, Puig PL, Kroemer G. Le Naour J, et al. Oncoimmunology. 2023 Jul 21;12(1):2237354. doi: 10.1080/2162402X.2023.2237354. eCollection 2023. Oncoimmunology. 2023. PMID: 37492227 Free PMC article.
The ambiguous role of FPR1 in immunity and inflammation.
Vacchelli E, Le Naour J, Kroemer G. Vacchelli E, et al. Among authors: le naour j. Oncoimmunology. 2020 Apr 30;9(1):1760061. doi: 10.1080/2162402X.2020.1760061. eCollection 2020. Oncoimmunology. 2020. PMID: 32391192 Free PMC article. No abstract available.
Trial watch: TLR3 agonists in cancer therapy.
Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E. Le Naour J, et al. Oncoimmunology. 2020 Jun 2;9(1):1771143. doi: 10.1080/2162402X.2020.1771143. Oncoimmunology. 2020. PMID: 32934877 Free PMC article. Review.
Trial watch: STING agonists in cancer therapy.
Le Naour J, Zitvogel L, Galluzzi L, Vacchelli E, Kroemer G. Le Naour J, et al. Oncoimmunology. 2020 Jun 16;9(1):1777624. doi: 10.1080/2162402X.2020.1777624. Oncoimmunology. 2020. PMID: 32934881 Free PMC article. Review.
Trial watch: IDO inhibitors in cancer therapy.
Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E. Le Naour J, et al. Oncoimmunology. 2020 Jun 14;9(1):1777625. doi: 10.1080/2162402X.2020.1777625. Oncoimmunology. 2020. PMID: 32934882 Free PMC article. Review.
A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency.
Le Naour J, Liu P, Zhao L, Adjemian S, Sztupinszki Z, Taieb J, Mulot C, Silvin A, Dutertre CA, Ginhoux F, Sauvat A, Cerrato G, Castoldi F, Martins I, Stoll G, Paillet J, Mangane K, Richter C, Kepp O, Maiuri MC, Pietrocola F, Vandenabeele P, André F, Delaloge S, Szallasi Z, Laurent-Puig P, Zucman-Rossi J, Zitvogel L, Pol JG, Vacchelli E, Kroemer G. Le Naour J, et al. Cancer Discov. 2021 Feb;11(2):408-423. doi: 10.1158/2159-8290.CD-20-0465. Epub 2020 Oct 12. Cancer Discov. 2021. PMID: 33046534
No impact of cancer and plague-relevant FPR1 polymorphisms on COVID-19.
Petrazzuolo A, Le Naour J, Vacchelli E, Gaussem P, Ellouze S, Jourdi G, Solary E, Fontenay M, Smadja DM, Kroemer G. Petrazzuolo A, et al. Among authors: le naour j. Oncoimmunology. 2020 Dec 8;9(1):1857112. doi: 10.1080/2162402X.2020.1857112. Oncoimmunology. 2020. PMID: 33344044 Free PMC article.
A major genetic accelerator of cancer diagnosis: rs867228 in FPR1.
Sztupinszki Z, Le Naour J, Vacchelli E, Laurent-Puig P, Delaloge S, Szallasi Z, Kroemer G. Sztupinszki Z, et al. Among authors: le naour j. Oncoimmunology. 2021 Jan 6;10(1):1859064. doi: 10.1080/2162402X.2020.1859064. Oncoimmunology. 2021. PMID: 33489470 Free PMC article. No abstract available.
26 results